Evidence map›Paper›PMID 28701470›Full record

Trial reportCirculation2017

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.

Dirk J van Veldhuisen, Piotr Ponikowski, Peter van der Meer, Marco Metra, Michael Böhm, Artem Doletsky, Adriaan A Voors, Iain C Macdougall, Stefan D Anker, Bernard Roubert and 3 more

2 registry-linked trialsAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 199 papers, 22 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed, 22 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01394562 phase3completednot on this map

Multicentre, Prospective, Randomised, 2-arm Study to Assess the Impact of Ferric Carboxymaltose on Exercise Capacity in Chronic Heart Failure Patients With Iron Deficiency

TypeinterventionalSponsorVifor PharmaRan2011 to 2016Enrolled174ConditionsIron Deficiency, Chronic Heart FailureArmsFerinject (ferric carboxymaltose), Standard of Care
NCT04608539 phase4completednot on this mapstarted 2021, after this paper: background citation

The Postoperative Iron in Cardiac Surgery (PICS-) Trial: A Randomised Clinical Trial Comparing the Efficacy of Single-, High-dose Intravenous Iron and Oral Iron for the Treatment of Anaemia Following Cardiac Surgery

TypeinterventionalSponsorMichael KremkeRan2021 to 2023Enrolled110ConditionsAnemia PostoperativeArmsFerric Derisomaltose, Ferrous sulfate, normal saline
3 · Its place in the literature

Who cites it

199 citing papers in PubMed, 22 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2023
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

139 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Dirk J van VeldhuisenFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.). d.j.van.veldhuisen@umcg.nl.
Piotr PonikowskiFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
Peter van der MeerFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
Marco MetraFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
Michael BöhmFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
Artem DoletskyFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
Adriaan A VoorsFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
Iain C MacdougallFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
Stefan D AnkerFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
Bernard RoubertFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
Lorraine ZakinFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
Alain Cohen-SolalFrom Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.v.V., P.v.d.M., A.A.V.); Department of Heart Diseases, Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Department of Cardiology, University Hospital, Brescia, Italy (M.M.); Universitätsklinikum des Saarlandes, Homburg/Saar, Germany (M.B.); I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.D.); King's College Hospital, London, United Kingdom (I.C.M.); Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (S.D.A.); Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin (S.D.A.); Charité Universitätsmedizin Berlin, Germany (S.D.A.); Department of Cardiology and Pneumology, University Medicine Göttingen, Germany (S.D.A.); Vifor Pharma, Glattbrugg, Switzerland (B.R., L.Z.); and Hopital Lariboisiere, University Paris Diderot, UMR-S942, France (A.C.-S.).
EFFECT-HF Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIron deficiency is common in patients with heart failure (HF) and is associated with reduced exercise capacity and poor outcomes. Whether correction of iron deficiency with (intravenous) ferric carboxymaltose (FCM) affects peak oxygen consumption [peak VO

methodsWe studied patients with systolic HF (left ventricular ejection fraction ≤45%) and mild to moderate symptoms despite optimal HF medication. Patients were randomized 1:1 to treatment with FCM for 24 weeks or standard of care. The primary end point was the change in peak VO

resultsA total of 172 patients with HF were studied and received FCM (n=86) or standard of care (control group, n=86). At baseline, the groups were well matched; mean age was 64 years, 75% were male, mean left ventricular ejection fraction was 32%, and peak VO

conclusionsTreatment with intravenous FCM in patients with HF and iron deficiency improves iron stores. Although a favorable effect on peak VO CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01394562.

Indexed as

Heart FailureAgedBiomarkersExercise ToleranceFemaleFerric CompoundsFerritinsHumansIron DeficienciesMaleMaltoseMiddle AgedOxygenQuality of LifeStroke VolumeTransferrinBiomarkersferric carboxymaltoseFerric CompoundsFerritinsMaltoseOxygenTransferrinexercise capacityferric carboxymaltoseheart failureiron deficiency

Identifiers

PMID28701470
PMCPMC5642327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.